logo
Plus   Neg
Share
Email

Bristol-Myers Squibb Boosts FY19 Adj. EPS Outlook - Quick Facts

While reporting financial results for the third quarter on Thursday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) slashed its earnings guidance for the full-year 2019, while raising full year adjusted earnings outlook.

For fiscal 2019, the company now projects earnings in a range of $3.46 to $3.56 per share and adjusted earnings in a range of $4.25 to $4.35 per share.

Previously, the company expected earnings in the range of $3.73 to $3.83 per share and adjusted earnings in the range of $4.20 to $4.30 per share.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $4.28 per share for the year. Analysts' estimates typically exclude special items.

The company said it continues to advance the planned acquisition of Celgene and the transaction closing. The company added that the guidance inclusive of the Celgene acquisition will be provided after the close of the transaction.

For the third quarter, the company reported net earnings attributable to Bristol-Myers Squibb of $1.35 billion, or $0.83 per share, down from $1.90 billion, or $1.16 per share in the prior-year quarter. Adjusted net earnings per share attributable to Bristol-Myers Squibb were $1.17, compared to last year's $1.09.

Bristol-Myers Squibb posted third-quarter revenues of $6.01 billion, an increase of 6 percent from the same period a year ago. Revenues increased 7 percent when adjusted for foreign exchange impact.

Analysts expected quarterly earnings of $1.07 per share on revenues of 5.89 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. (AAPL) Wednesday reported a first-quarter profit that trumped Wall Street estimates, as the iPhone maker reported its "highest quarterly revenue ever" driven by strong demand for its iPhone 11 and 11 Pro models during the holiday season. The tech giant also issued a strong revenue outlook... New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry. Graco Inc. (GGG) shares were climbing more than 7 percent in morning trade. Monday after market close, the company had reported a surge in the fourth-quarter earnings to $84.8 million from $73.7 million in the prior year. Earnings per share surpassed analysts' estimates. Sales were up 1 percent to $412.3...
Follow RTT
>